Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K F. Rooney

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
European Journal of Pharmacology|September 22, 1989
Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociceptionK F Rooney, R D Sewell
Drug Discovery Today|July 27, 2001
Modelling and simulation in clinical drug developmentK F. Rooney, E Snoeck, P H. Watson
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1991
Increased dopamine receptor sensitivity in the rat following acute administration of sufentanil, U50,488H and D-Ala2-D-Leu5-enkephalinK F Rooney, R A Armstrong, R D Sewell
Psychopharmacology|January 1, 1988
Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphanS J Livingston, R D Sewell, K F Rooney, et al.
Lancet (London, England)|September 6, 1986
Dopamine D2 receptors and SCH 23390 treatmentK F Rooney, R D Sewell, P S Spencer, et al.
British Journal of Haematology|December 1, 1990
Lennert's lymphoma: response to 2'-deoxycoformycinR M Lowenthal, J S Wiley, K F Rooney, et al.
British Journal of Pharmacology|January 1, 1987
Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390S Barasi, M M Ben-Sreti, A L Clatworthy, et al.
Australian and New Zealand Journal of Ophthalmology|May 1, 1989
Tinted lenses and dyslexics--a controlled study. SPELD (S.A.) Tinted Lenses Study GroupG A Gole, S N Dibden, C C Pearson, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
Leukemia & Lymphoma|September 24, 1999
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG)R M Lowenthal, K F Bradstock, J P Matthews, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
European Journal of Pharmacology|September 22, 1989
Evaluation of selective actions of dopamine D-1 and D-2 receptor agonists and antagonists on opioid antinociceptionK F Rooney, R D Sewell
Drug Discovery Today|July 27, 2001
Modelling and simulation in clinical drug developmentK F. Rooney, E Snoeck, P H. Watson
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 1, 1991
Increased dopamine receptor sensitivity in the rat following acute administration of sufentanil, U50,488H and D-Ala2-D-Leu5-enkephalinK F Rooney, R A Armstrong, R D Sewell
Psychopharmacology|January 1, 1988
Amelioration of naloxone-precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphanS J Livingston, R D Sewell, K F Rooney, et al.
Lancet (London, England)|September 6, 1986
Dopamine D2 receptors and SCH 23390 treatmentK F Rooney, R D Sewell, P S Spencer, et al.
British Journal of Haematology|December 1, 1990
Lennert's lymphoma: response to 2'-deoxycoformycinR M Lowenthal, J S Wiley, K F Rooney, et al.
British Journal of Pharmacology|January 1, 1987
Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390S Barasi, M M Ben-Sreti, A L Clatworthy, et al.
Australian and New Zealand Journal of Ophthalmology|May 1, 1989
Tinted lenses and dyslexics--a controlled study. SPELD (S.A.) Tinted Lenses Study GroupG A Gole, S N Dibden, C C Pearson, et al.
Cancer Treatment Reports|December 1, 1987
Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patientsR M Lowenthal, C N Chesterman, J D Griffiths, et al.
Leukemia & Lymphoma|September 24, 1999
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG)R M Lowenthal, K F Bradstock, J P Matthews, et al.
Pageof 1